Tisagenlecleucel

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

INN	Tisagenlecleucel
Medicine type	Biological agent
EML status history	Application rejected in 2023 (TRS 1049) for Diffuse large B-cell lymphomas
Therapeutic equivalent for	axicabtagene ciloleucel for Diffuse large B-cell lymphomas
Wikipedia	Tisagenlecleucel
DrugBank	Tisagenlecleucel